Posted by Michael Wonder on 03 Dec 2024
The trade-off between accelerated cancer drug approvals and patient preferences
18 November 2024 - Cancer care stands at a critical juncture where the urgency of rapid drug approvals must be balanced against the need for enduring patient centric benefits.
Robin Forrest and colleagues conducted a discrete choice experiment based on a survey of US adults with direct or familial lived cancer experience, to elucidate the perceived, self-reported trade-off between early access to novel cancer treatments and the therapeutic benefits portended.
